FDA Fixes Fee Fumble for Rare Disease Fast-Track Vouchers
Published Date: 7/28/2026
Notice
Summary
The FDA fixed some details about the fee for using a Priority Review Voucher in 2026. If you're submitting a drug application using one of these special vouchers, you now have to pay the fee right when you submit your application. This change affects companies working on rare pediatric diseases, tropical diseases, or medical countermeasures, and it kicks in starting February 3, 2026.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Priority Review Fee Due at Submission
If you are a sponsor using a priority review voucher for a rare pediatric disease, tropical disease, or material threat medical countermeasure, the priority review user fee must be paid when you submit the human drug application. This reflects the February 3, 2026 amendment to section 529 of the FD&C Act and applies to submissions under section 505(b)(1) or section 351(a).
Form FDA 3397 Voucher Selection Hold
Form FDA 3397 (Prescription Drug User Fee Coversheet) is updated to let sponsors select use of a rare pediatric disease priority review voucher. If you select a tropical disease, material threat MCM, or rare pediatric disease voucher on Form FDA 3397, the form will be placed on hold while FDA reviews the voucher redemption; after the hold is lifted you may complete the form and pay the fees.
Rolling Review Submission Date Clarified
For a "rolling review" application where a tropical disease, rare pediatric disease, or material threat MCM priority review voucher is redeemed, FDA will treat the application as submitted on the date FDA receives the final portion that the applicant identifies as complete. This follows FDA's May 2014 guidance on expedited programs.
Use Pay.gov Unique User Fee ID
For all priority reviews, sponsors must use the unique user fee ID number generated for the Pay.gov feature when making wire transfers or payments. This instruction replaces prior wording in the wire transfer payment process section.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18529, Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
The FDA wants your thoughts on how they collect info to track medical devices. This affects companies that make or handle these devices and aims to keep things safe and clear. You’ve got until November 10, 2026, to share your comments—no cost, just your voice!
2026-18612, Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18551, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
Previous / Next Documents
Previous: 2026-15151, Sunshine Act Meetings
Next: 2026-15148, Agency Information Collection Activities; Proposed Collection; Comment Request; Expanded Access to Investigational Drugs for Treatment Use
The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with expanded access to investigational drugs for treatment use.